Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)

A technology of ferritin and hemoglobin, which is used in anti-growth factor immunoglobulin, blood diseases, disease diagnosis, etc.

Pending Publication Date: 2019-10-25
NOVARTIS AG
View PDF127 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although therapeutic options currently exist for the treatment of anemia-related diseases and conditions, there remains a need for improved anemia treatments that are effective and well tolerated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
  • Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
  • Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0620] Example 1 - In vitro and in vivo activity and PK / PD of anti-BMP6 antibodies

[0621] Material

[0622] Test compounds were antibodies 5, 6 and 7 at a concentration of approximately 8 mg / ml in 50 mM citrate buffer, pH 7.0, 150 mM NaCl (Table 8) and diluted in PBS prior to animal dosing. Male C56BL / 6 mice or Sprague Dawley rats were used (Table 9).

[0623] Table 8. Characteristics of BMP6 antagonist antibodies

[0624]

[0625]

[0626] Table 9. Animal Characteristics

[0627]

[0628] For the BMP reporter assay, a lentiviral vector containing the BMP response element BRE in the promoter was constructed [Korchynskyi et al. 2002. J. Biol. Chem. 277:4882-91], thereby driving - Firefly luciferase from BRE2-Luc2. Lentiviral vectors were used for stable transfection of the HEP3B hepatoma cell line. Cell lines were maintained in EMEM containing 10% fetal bovine serum, 1% penicillin / streptomycin and 5ug / ml blasticidin. Recombinant human BMP protein was purchased ...

example 2

[0667] Example 2 - Clinical Program for Testing BMP6 Antibodies in Humans Clinical Trial Program: Evaluation of therapies using antibodies or antigen-binding fragments thereof that bind human BMP6.

[0668]Patients with end-stage renal disease (ESRD) produce little, if any, erythropoietin (EPO) and often require regular administration of exogenous EPO and intravenous (IV) infusion of iron to achieve EPO-induced Hgb synthesis . Up to one-third of chronic hemodialysis (HD) patients do not respond adequately to EPO, primarily due to intracellular sequestration of iron. Hepcidin is primarily eliminated by the kidneys, with insufficient clearance by dialysis. Thus, chronic HD patients tend to have significantly elevated levels of hepcidin, which blocks the mobilization of iron for erythropoiesis. Once body iron stores reach critical levels (indicated by high serum ferritin levels), IV iron therapy is no longer effective or recommended. Current guidelines advise against administe...

example 3

[0836] Example 3: TSAT levels in patients treated with 0.01 mg / kg Antibody 7

[0837] Data including TSAT (iron saturation, %) levels were evaluated for the first 10 patients treated according to the clinical protocol described in Example 2, where each patient received a single infusion of Antibody 7 at 0.01 mg / kg. None of these patients showed any hepatic safety signal defining a no-observed adverse effect level (NOAEL) of 0.1 mg / kg / week. Cohort 1 included 5 anemic hemodialysis patients with low ferritin levels less than or equal to 500 ng / mL, while cohort 2 included 5 anemic hemodialysis patients with higher ferritin levels (500 to 1000 ng / mL).

[0838] Among the five Cohort 1 (low ferritin) patients receiving 0.01 mg / kg of Antibody 7, post-dose TSAT levels increased by an average of only 9.8% (average post-dose 38.6% vs. pre-dose 24.8%). In contrast, among the five Cohort 2 (high ferritin) patients receiving 0.01 mg / kg Antibody 7, TSAT levels increased by an average of 17....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates methods of treatment using BMP6 antagonists.

Description

[0001] sequence listing [0002] The application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. Said ASCII copy, created on May 23, 2017, is named PAT057354-WO-PCT_SL.txt and is 82,879 bytes in size. [0003] introduction [0004] The present invention relates to methods of treating anemia using inhibitors of bone morphogenetic protein 6 (BMP6). Background technique [0005] Anemia is prevalent in patients with chronic kidney disease (CKD) and is associated with lower quality of life and higher risk of adverse outcomes, including cardiovascular disease and death. Several approaches to the management of anemia in patients with CKD include the use of erythropoiesis-stimulating agents (ESAs), oral and intravenous iron supplementation, and blood transfusions. However, many patients do not respond adequately to these treatments or require higher doses of ESA and / or iron. High doses of i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/395A61K31/00G01N33/00G01N33/68A61P7/00
CPCC07K16/22G01N33/6893A61K2039/505C07K2317/76C07K2317/94G01N2333/51G01N2800/22A61P7/06A61K39/00A61K39/3955A61K2039/545A61K2039/54G01N2800/52C07K14/505C07K2317/24C07K2317/55C07K2317/565C07K2317/622C07K2317/92A61K38/1816
Inventor 丛枫W·迪特里希N·乔治刘东A·沙赫特A·索尼周劲
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap